![Bruce Goldsmith](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Bruce Goldsmith
Private Equity Investor bei
Alsa Management Services Ltd
Profil
Bruce A. Goldsmith is currently Operating Partner at Alsa Management Services Ltd. Former roles include President, Chief Executive Officer & Director at Passage Bio, Inc. from 2021 to 2022; Chief Executive Officer at Civetta Therapeutics LLC from 2019 to 2020; Product Director at Johnson & Johnson; Venture Partner at Deerfield Management Co. LP from 2019 to 2020; Senior Vice President-Corporate Development at Allos Therapeutics, Inc. from 2011 to 2012; Venture Partner at Deerfield Management Co. LP (Private Equity); Chief Operating Officer at Lycera Corp.
from 2013 to 2019; and Vice President-Strategic Marketing at GPC Biotech, Inc. Education includes an undergraduate degree from Colgate University in 1987, a doctorate from the University of Pennsylvania in 1993, and an MBA from Columbia Business School in 1999.
Aktive Positionen von Bruce Goldsmith
| Unternehmen | Position | Beginn |
|---|---|---|
Alsa Management Services Ltd
 Alsa Management Services Ltd Investment ManagersFinance ALSA Ventures invests in companies located in the United Kingdom. The firm focuses on sectors such as therapeutics and biotechnology. It participates in early stage capital transactions. | Private Equity Investor | - |
Ehemalige bekannte Positionen von Bruce Goldsmith
| Unternehmen | Position | Ende |
|---|---|---|
| PASSAGE BIO, INC. | Vorstandsvorsitzender | 31.05.2022 |
Civetta Therapeutics LLC
 Civetta Therapeutics LLC Pharmaceuticals: MajorHealth Technology Manufactures therapeutics for cancers and other diseases | Vorstandsvorsitzender | 01.01.2020 |
Deerfield Management Co. LP
 Deerfield Management Co. LP Investment ManagersFinance Deerfield conducts extensive fundamental research into healthcare sector assets and investment opportunities. The firm makes use of this fundamental research to identify investment opportunities, determine how best to structure or “express” an investment thesis, direct the purchase and sale of securities, negotiate structured investment transactions, and generally manage and invest the assets of the Funds. The majority of Fund investments are made in companies that are organized in the United States or that issue securities available in the US public securities markets. | Corporate Officer/Principal | 01.01.2020 |
Lycera Corp.
 Lycera Corp. Pharmaceuticals: MajorHealth Technology Develops novel oral medicines for treating autoimmune diseases and cancer | Geschäftsführer | 01.01.2019 |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets anti-cancer therapeutics | Corporate Officer/Principal | 05.09.2012 |
Ausbildung von Bruce Goldsmith
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
91
Beziehungen ersten Grades
12
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 12 |
|---|---|
Johnson & Johnson
 Johnson & Johnson Pharmaceuticals: MajorHealth Technology Operates as an investment holding company with interests in health care products | Health Technology |
Deerfield Management Co. LP
Deerfield Management Co. LP Investment ManagersFinance Deerfield conducts extensive fundamental research into healthcare sector assets and investment opportunities. The firm makes use of this fundamental research to identify investment opportunities, determine how best to structure or “express” an investment thesis, direct the purchase and sale of securities, negotiate structured investment transactions, and generally manage and invest the assets of the Funds. The majority of Fund investments are made in companies that are organized in the United States or that issue securities available in the US public securities markets. | Finance |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets anti-cancer therapeutics | Health Technology |
Lycera Corp.
Lycera Corp. Pharmaceuticals: MajorHealth Technology Develops novel oral medicines for treating autoimmune diseases and cancer | Health Technology |
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
GPC Biotech, Inc.
 GPC Biotech, Inc. Drugstore ChainsRetail Trade Develops anticancer drugs | Retail Trade |
Colgate University
 Colgate University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Columbia Business School
 Columbia Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Deerfield Management Co. LP (Private Equity)
 Deerfield Management Co. LP (Private Equity) Investment ManagersFinance Deerfield Management invests in both private and public companies located in the United States. The firm targets companies operating in the fields of diagnostic, digital health, life science, medical device, and health care services. It provides financing for pre-seed, seed, early, later and growth stage capital requirements. | Finance |
Passage Bio, Inc.
 Passage Bio, Inc. BiotechnologyHealth Technology Develops therapies for the treatment of monogenic central nervous system disorders | Health Technology |
Civetta Therapeutics LLC
Civetta Therapeutics LLC Pharmaceuticals: MajorHealth Technology Manufactures therapeutics for cancers and other diseases | Health Technology |
Alsa Management Services Ltd
Alsa Management Services Ltd Investment ManagersFinance ALSA Ventures invests in companies located in the United Kingdom. The firm focuses on sectors such as therapeutics and biotechnology. It participates in early stage capital transactions. | Finance |
